Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myconostica CE marks MycAssay tests on new platforms

This article was originally published in Clinica

Executive Summary

UK diagnostics specialist Myconostica has CE marked its MycAssay Aspergillus and Pnuemocystis tests for use on Roche's Lightcycler 2.0 and Stratagene's Mx3000 system. The products had previously been CE marked for use with Cepheid's Smartcycler and Applied Biosystems' ABI 7500. Together, these devices are the four most common real-time PCR machines in clinical microbiology and mycology labs, Manchester-based Myconostica claims. The first test detects Aspergillus species, one of the most common causes of fungal pneumonia. The second detects Pnuemocystis jirovecii; this fungus can cause pneumonia in immunocompromised people. Both tests can product results in three hours when used with the firm's MycXtra fungal DNA extraction system, using lower respiratory tract samples.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT095345

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel